respiratori
mucosa
vulner
invas
number
import
human
pathogen
includ
varieti
virus
profici
mucos
antigenspecif
immun
respons
essenti
prevent
disrupt
critic
function
may
substanti
impair
cours
respiratori
viru
infect
unfortun
sever
respiratori
complic
tend
occur
first
exposur
young
children
among
elderli
immunocompet
begun
erod
vaccin
effect
target
popul
need
provid
protect
urgent
need
passiv
transfer
specif
immunoglobulin
gener
protect
respiratori
viru
infect
two
vaccin
respiratori
virus
influenza
adenoviru
licens
use
neither
vaccin
highli
effect
neither
recommend
use
children
less
year
age
difficulti
design
benefici
mucos
vaccin
compound
fact
mucos
immun
system
appear
prone
polar
toward
either
helper
th
type
domin
latter
actual
lead
immunemedi
airway
obstruct
diseas
complet
understand
mechan
underli
polar
could
well
lead
superior
strategi
prime
mucos
immun
system
respiratori
pathogen
import
manifest
sinc
viral
agent
lead
caus
morbid
among
adult
mortal
among
young
elderli
notabl
person
centuri
perish
influenza
pandem
perish
world
war
follow
summari
salient
featur
pathogenesi
respiratori
virus
respons
greatest
public
health
impact
togeth
current
anticip
progress
vaccin
develop
includ
use
adjuv
biolog
modifi
enhanc
vaccin
perform
pathogen
caus
largest
burden
respiratori
diseas
human
includ
influenza
flu
viru
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
rhinovirus
coronavirus
adenovirus
influenza
singlestrand
negativesens
rna
viru
belong
orthomyxoviru
famili
classifi
influenza
virus
b
c
influenza
viru
genom
divid
seven
influenza
c
eight
influenza
b
segment
encod
variabl
number
gene
product
influenza
virus
share
properti
bind
mucu
sialic
acidbear
cell
surfac
receptor
three
type
distinguish
basi
antigen
differ
nucleocapsid
matrix
protein
wright
webster
influenza
virus
commonli
respons
sever
respiratori
ill
human
follow
influenza
b
influenza
c
rare
respons
lower
respiratori
diseas
human
influenza
virus
distinguish
rapid
antigen
variat
accomplish
two
mechan
antigen
shift
antigen
drift
antigen
shift
result
recombin
hemagglutinin
ha
neuraminidas
na
gene
parent
strain
process
believ
involv
intermedi
anim
host
particularli
migratori
waterfowl
pig
fifteen
ha
nine
na
subtyp
identifi
antigen
drift
result
continu
mutat
chang
ha
na
protein
shift
variant
emerg
constantli
previous
induc
antibodi
reduc
avid
respons
annual
epidem
influenzath
period
emerg
shift
variant
larg
number
peopl
popul
histori
exposur
lead
influenza
pandem
type
variat
pose
consider
problem
influenza
vaccin
strategi
current
make
annual
vaccin
updat
vaccin
formul
essenti
control
influenza
diseas
influenza
virus
replic
rapidli
highli
infecti
spread
princip
aerosol
influenza
infect
primarili
upper
respiratori
tract
cours
infect
viru
spread
lower
respiratori
tract
caus
viral
pneumonia
enhanc
suscept
bacteri
infect
viru
replic
peak
within
hour
exposur
slowli
declin
approxim
week
wright
webster
upon
recoveri
patient
perman
immun
reinfect
ident
strain
may
fulli
suscept
shift
variant
protect
symptomat
infect
drift
variant
usual
persist
sever
year
frank
et
al
influenza
infect
major
caus
morbid
mortal
area
world
result
least
death
hospit
annual
unit
state
center
diseas
control
prevent
cdc
infect
occur
frequent
children
adult
elderli
regard
highest
risk
group
lifethreaten
diseas
webster
young
children
person
age
chronic
lung
disord
also
high
risk
seriou
complic
death
influenza
infect
rel
import
innat
humor
cellular
mucos
immun
control
protect
influenza
viru
infect
remain
poorli
understood
high
level
proinflammatori
cytokin
interferon
ifn
induc
influenza
infect
usual
peak
day
kaiser
et
al
cytokin
believ
play
direct
role
impair
viral
infect
drive
immun
respons
toward
cytokin
pattern
transient
infiltr
natur
killer
nk
cell
also
observ
influenza
infect
suggest
import
earli
defens
mechan
skoner
et
al
neutrophil
also
play
import
role
clearanc
viru
lung
mice
irradi
reduc
number
peripher
polymorphonuclear
leukocyt
increas
viral
titer
influenza
infect
lung
wright
webster
addit
defici
compon
complement
welldescrib
opsonin
activ
also
result
impair
abil
clear
influenza
wright
webster
howev
enthusiasm
nonspecif
defens
must
temper
observ
function
poorli
shift
variant
particularli
popul
greatest
risk
thu
innat
defens
would
seem
inadequ
alon
prevent
control
influenza
infect
moreov
influenza
viru
directli
impair
neutrophil
function
appear
respons
reduc
capac
clear
bacteri
infect
complic
pneumonia
ruben
cate
levin
et
al
presenc
antibodi
specif
ha
na
absolut
requir
prevent
influenza
infect
webster
mucos
iga
antibodi
nasal
bronchial
secret
appear
particularli
effect
neutral
influenza
viru
may
also
play
import
role
viral
clearanc
tamura
et
al
humor
igg
antibodi
ha
na
also
produc
respons
influenza
enhanc
resist
influenza
viru
infect
human
anim
model
wright
webster
neutral
antibodi
influenza
direct
surfac
glycoprotein
ha
na
thu
specif
influenza
subtyp
ie
homosubtyp
cell
respons
contrast
predominantli
direct
epitop
invari
protein
np
matrix
protein
thu
influenza
typespecif
heterosubtyp
result
studi
compar
mucos
system
immun
suggest
former
induc
effect
memori
respons
latter
gors
belsh
clover
et
al
et
al
role
cell
prevent
influenza
infect
especi
human
well
defin
howev
sinc
cell
respons
direct
mainli
share
protein
among
strain
protect
would
expect
highli
crossreact
fact
human
crossprotect
occur
among
drift
variant
effect
level
crossreact
detect
antibodi
high
wright
webster
relev
crossreact
cell
immun
influenza
studi
mice
circumst
antibodymedi
crossreact
ha
na
epitop
avoid
studi
effect
crossprotect
occur
month
appear
princip
involv
effector
memori
cytotox
lymphocyt
ctl
present
alveolar
space
interstiti
tissu
respiratori
tract
woodland
hogan
et
al
although
similar
cell
may
present
drain
lymphoid
tissu
cell
seem
particip
protect
respons
month
postprimari
infect
mucos
effector
memori
cell
larg
disappear
longer
particip
directli
immun
reinfect
circumst
lack
crossreact
antibodi
cellprim
anim
becom
suscept
clinic
diseas
upon
challeng
although
syndrom
may
shorter
milder
sever
occur
challeng
anim
woodland
accordingli
cell
would
seem
play
best
minor
role
effect
resist
secondari
infect
except
immedi
postprimari
infect
period
less
known
function
cell
mediat
protect
reinfect
howev
also
believ
cell
mice
least
play
littl
role
mediat
protect
secondari
infect
nevertheless
cell
respons
requir
optim
antibodi
respons
influenza
protein
may
also
need
robust
cell
respons
epstein
et
al
function
cell
immun
mainli
requir
effect
recoveri
infect
primari
infect
chiefli
function
cell
may
larg
involv
cytotox
cytokin
product
cerwenka
et
al
sarawar
et
al
mous
cell
respons
becom
evid
around
day
primari
infect
peak
day
time
correspond
viral
clearanc
eichelberg
et
al
flynn
et
al
riberdi
et
al
induct
cell
respons
occur
nasal
associ
lymphoreticular
tissu
nalt
drain
lymph
node
howev
effector
cell
respons
viral
clearanc
lung
like
deriv
larg
mucos
lymphoid
site
crucial
outcom
primari
infect
establish
immunolog
memori
mous
cell
memori
cell
found
nonlymphoid
lymphoid
site
memori
nonlymphoid
site
includ
respiratori
tract
shorter
durat
lymphoid
memori
hogan
et
al
recal
site
take
least
day
circumst
explain
cell
readili
avail
contain
infect
earli
stage
infect
howev
cell
recruit
activ
effector
cell
particip
viral
clearanc
cell
function
produc
type
cytokin
particularli
recent
understand
immun
murin
influenza
may
implic
regard
vaccin
design
thu
would
seem
mucos
memori
import
goal
vaccin
influenza
moreov
suspect
differ
type
vaccin
may
variabl
stimul
longterm
mucos
system
memoryth
immun
respons
influenza
thu
complex
craft
effect
vaccin
strategi
requir
account
varieti
factor
includ
rout
inocul
vaccin
composit
type
strain
variat
inactiv
influenza
vaccin
current
use
unit
state
compris
three
split
influenza
strain
strain
select
basi
previou
year
surveil
data
preval
subtyp
vaccin
composit
may
vari
year
year
particularli
influenza
compon
contrast
natur
infect
intramuscular
inocul
inactiv
trival
influenza
vaccin
induc
product
serum
antibodi
effect
induc
mucos
cellmedi
immun
respons
influenzaspecif
system
antibodi
transud
lung
credit
vaccin
formul
observ
reduct
sever
lower
respiratori
tract
diseas
nonetheless
immun
elicit
inactiv
parenter
administ
vaccin
strainspecif
short
durat
make
annual
revaccin
necessari
addit
protect
rate
vari
age
group
especi
low
popul
suscept
diseas
complic
death
elderli
infant
person
chronic
pulmonari
condit
wright
webster
basi
reduc
efficaci
vaccin
elderli
well
understood
studi
various
implic
heterogen
respons
compon
strain
type
adapt
immun
respons
gener
webster
remarqu
treanor
falsey
bernstein
et
al
sinc
respiratori
infect
influenza
induc
humor
mucos
antibodi
well
crossreact
cellmedi
immun
cmi
wide
believ
although
proven
vaccin
efficaci
improv
nasal
administr
number
nasal
vaccin
strategi
investig
includ
use
live
attenu
strain
bradshaw
wright
belsh
gruber
et
al
murphi
recombin
berglund
et
al
ferko
et
al
watanab
et
al
virosom
cusi
et
al
dna
ljungberg
et
al
ban
et
al
peptid
matsuki
et
al
yedidia
et
al
jeon
arnon
purifi
subunit
vaccin
barchfield
et
al
asanuma
et
al
saurweinteissl
et
al
immunestimul
complex
iscom
et
al
et
al
nasal
administ
live
attenu
coldadapt
trival
influenzaviru
vaccin
ca
vaccin
may
repres
conveni
effect
approach
prevent
influenza
children
segment
genom
characterist
influenza
facilit
reassort
two
strain
dualli
infect
individu
cell
exploit
phenomenon
vaccin
antigen
updat
annual
substitut
gene
encod
ha
na
antigen
contemporari
influenza
b
virus
present
establish
master
attenu
strain
bradshaw
wright
ca
vaccin
administ
spray
devic
deliv
aerosol
larg
particl
upper
respiratori
tract
vaccin
extens
fieldtest
subject
rang
month
year
age
well
toler
immunogen
protect
particularli
young
children
belsh
et
al
belsh
et
al
edward
et
al
treanor
et
al
boyc
et
al
gruber
et
al
murphi
one
field
trial
seroneg
children
individu
virus
present
vaccin
induc
fourfold
greater
increas
titer
recipi
belsh
et
al
clinic
trial
involv
particip
age
reveal
inactiv
vaccin
induc
higher
level
serum
antibodi
live
vaccin
latter
induc
much
higher
level
mucos
immun
edward
et
al
vaccin
shown
induc
strainspecif
mucos
iga
major
children
two
dose
challeng
studi
adult
volunt
protect
efficaci
ca
vaccin
estim
compar
current
avail
inactiv
vaccin
separ
studi
children
age
vaccin
determin
effect
prevent
cultureconfirm
influenza
b
infect
one
earli
studi
influenza
vaccin
children
suggest
risk
acquir
influenza
infect
age
group
could
reduc
substanti
communitywid
coverag
level
achiev
young
children
monto
kioumehr
consid
achiev
goal
ca
vaccin
larg
part
nasal
rout
administr
readili
accept
subcutan
intramuscular
inject
particularli
children
ca
vaccin
associ
side
effect
gener
mild
recipi
found
slightli
elev
risk
rhinorrhea
lowgrad
fever
belsh
et
al
elev
fever
also
observ
compar
fraction
inactiv
influenza
vaccin
recipi
ca
vaccin
associ
syndrom
observ
low
incid
inactivatedvaccin
recipi
laski
et
al
live
attenu
vaccin
appear
less
efficaci
elderli
one
studi
suggest
convent
inactiv
trival
vaccin
given
combin
nasal
ca
vaccin
may
enhanc
protect
elderli
recipi
treanor
bett
live
attenu
intranas
vaccin
licens
use
late
howev
advisori
committe
immun
practic
recommend
use
person
age
thu
vaccin
yet
avail
age
group
highest
risk
lifethreaten
diseas
harper
et
al
nasal
virosom
vaccin
consist
purifi
ha
na
encapsul
lecithin
also
evalu
clinic
trial
europ
studi
popul
includ
children
year
old
adult
elderli
year
old
vaccin
induc
influenzaspecif
system
igg
mucos
iga
estim
efficaci
adult
efficaci
children
highest
immunogen
seen
vaccin
coadminist
adjuv
lt
heatlabil
toxin
escherichia
coli
cusi
et
al
unfortun
vaccin
associ
increas
incid
bell
palsi
facial
paralysi
taken
market
semliki
forest
viru
sfv
recombin
vaccin
express
ha
na
shown
induc
protect
strainspecif
secretori
iga
siga
antibodi
respons
mice
sfv
recombin
vaccin
express
influenza
np
elicit
antigenspecif
ctl
protect
mice
infecti
challeng
berglund
et
al
iscom
includ
influenza
ha
na
administ
nasal
induc
protect
immun
mice
measur
antigenspecif
mucos
system
antibodi
cmi
helper
cytotox
activ
et
al
cytokin
profil
local
cell
respons
induc
iscom
shown
separ
studi
depend
upon
type
adjuv
use
et
al
suggest
plasmid
dna
vaccin
advantag
recombin
viral
vector
sfv
immun
respons
gener
vector
possibl
revaccin
indefinit
without
reduct
express
target
protein
nasal
plasmid
dna
vaccin
express
influenza
ha
evalu
mice
disappointingli
fail
elicit
detect
antibodi
respiratori
tract
ban
et
al
similar
vaccin
given
parenter
abl
induc
cmi
respons
ljungberg
et
al
howev
dna
vaccin
gener
effect
mice
human
fact
one
must
conclud
current
littl
enthusiasm
dna
vaccin
human
influenza
strategi
also
investig
vaccin
influenza
exampl
interest
exploit
common
mucos
immun
system
induc
respiratori
immun
deliv
vaccin
mucos
site
trial
oral
vaccin
thought
engag
intestin
peyer
patch
mean
particl
format
inert
microspher
contain
protein
antigen
repres
one
approach
investig
clanci
et
al
anoth
approach
studi
use
epiderm
powder
immun
trival
split
vaccin
administ
mice
compressedair
injector
initi
studi
demonstr
system
mucos
antibodi
well
enhanc
protect
infecti
challeng
chen
et
al
coadministr
almost
everi
candid
vaccin
variou
antigen
also
activ
explor
tactic
use
intranas
parenter
vaccin
induc
maxim
immun
given
intens
level
activ
field
seem
like
new
altern
current
use
vaccin
avail
within
rel
short
period
respiratori
syncyti
viru
rsv
import
caus
seriou
lower
respiratori
tract
ill
among
infant
children
unit
state
particularli
age
year
unit
state
alon
rsv
infect
account
hospit
thousand
death
year
health
care
cost
estim
sever
million
dollar
annual
shay
et
al
institut
medicin
togeth
parainfluenza
viru
two
virus
respons
nearli
onethird
case
respiratori
tract
diseas
necessit
hospit
children
hospit
result
rsv
infect
newborn
infant
prior
exposur
rsv
gener
hospit
infant
carri
recogn
risk
factor
sever
diseas
comparison
infant
age
develop
countri
throughout
world
rsv
lead
caus
morbid
mortal
among
infant
young
children
crow
et
al
respiratori
viru
infect
estim
caus
million
death
year
children
less
year
age
rsv
lead
contributor
death
rsv
also
signific
caus
sever
respiratori
tract
ill
elderli
immunocompromis
person
nicholson
et
al
walsh
et
al
infant
born
prematur
person
underli
heart
lung
diseas
notabl
bronchopulmonari
dysplasia
heighten
risk
develop
sever
rsv
diseas
hall
et
al
macdonald
et
al
groothiu
et
al
rsv
diseas
display
season
commun
outbreak
occur
winter
month
current
effect
treatment
rsv
diseas
although
prophylact
administr
rsv
antibodi
approv
highrisk
infant
appear
offer
protect
sever
diseas
rsv
respiratori
virus
implic
predispos
factor
develop
otiti
media
lead
specul
effect
vaccin
could
also
reduc
morbid
associ
diseas
anderson
rsv
spread
effici
among
infant
young
children
primari
infect
age
year
rsv
nonseg
negativestrand
rna
viru
member
paramyxoviridaeth
viru
code
protein
includ
three
transmembran
surfac
protein
g
f
sh
virion
matrix
protein
nucleocapsid
polymeras
protein
n
p
l
put
transcriptionrepl
regulatori
factor
two
nonstructur
protein
genom
consist
nucleotid
two
antigen
distinct
subgroup
rsv
character
basi
antigen
sequenc
variabl
rsv
rsv
b
subgroup
frequent
isol
commun
outbreak
appear
associ
frequent
sever
diseas
attach
glycoprotein
g
contain
observ
variabl
subgroup
strain
rsv
within
subgroup
display
high
level
antigen
similar
antigen
divers
subgroup
b
strain
high
g
high
fusion
protein
f
rsv
establish
infect
upper
respiratori
tract
replic
initi
nasopharynx
symptom
manifest
day
viru
spread
lower
tract
often
happen
suscept
age
group
sever
bronchiol
pneumonia
develop
within
day
symptom
persist
week
continu
viral
shed
except
immunocompromis
individu
viru
rare
spread
beyond
superfici
epithelium
lung
lesion
sever
diseas
like
consequ
direct
virusinduc
tissu
damag
along
immunopatholog
reaction
anim
model
play
import
role
acquir
inform
pathogenesi
rsv
brandenburg
et
al
mous
model
especi
use
permit
robust
studi
exampl
aim
defin
underli
mechan
respons
failur
formalininactiv
rsv
vaccin
anim
cotton
rat
nonhuman
primat
african
green
monkey
bonnet
monkey
chimpanze
also
provid
use
insight
rsv
diseas
model
infecti
agent
seriou
limit
howev
mice
instanc
fulli
permiss
rsv
infect
challeng
dose
caus
death
cotton
rat
suscept
infect
rang
immunolog
reagent
avail
mous
studi
avail
rat
high
bodi
temperatur
anim
complic
assess
attenu
temperaturesensit
strain
develop
vaccin
candid
nonhuman
primat
model
permit
essenti
preclin
studi
vaccin
toler
virul
anim
still
less
permiss
human
rsv
infect
critic
assess
candid
rsv
vaccin
need
perform
human
subject
ultim
involv
assess
youngest
vulner
popul
rsv
vaccin
need
target
immunolog
respons
rsv
complex
depend
multipl
factor
includ
age
patient
level
immunolog
matur
presenc
matern
passiv
transfer
antibodi
antigen
divers
rsv
allow
subgroup
circul
commun
time
exposur
rsv
one
subgroup
confer
shortliv
resist
diseas
subsequ
infect
altern
subgroup
protect
homotyp
subgroup
superior
sinc
antibodi
g
f
consid
princip
respons
resist
reinfect
sinc
intertyp
variat
greatest
protein
possibl
bival
rsv
vaccin
requir
achiev
optim
effect
humor
respons
rsv
direct
almost
exclus
f
g
surfac
glycoprotein
protein
major
neutral
target
mucos
serum
antibodi
sever
compon
immun
system
implic
control
resolut
rsv
infect
increas
resist
reinfect
observ
person
previous
infect
seem
mediat
primarili
rsvspecif
secretori
serum
antibodi
mill
et
al
princ
et
al
serum
igg
antibodi
protect
lower
upper
respiratori
tract
role
protect
latter
larg
provinc
siga
antibodi
although
antibodi
confer
protect
sever
diseas
protect
incomplet
multipl
reinfect
even
strain
take
place
despit
high
circul
titer
neutral
antibodi
recent
studi
antibodi
clone
natur
respons
rsv
reveal
viru
engin
evas
tactic
present
f
antigen
multipl
form
immun
respons
skew
antibodi
respons
toward
product
nonneutr
antibodi
sakurai
et
al
studi
also
reveal
neutral
power
antibodi
import
isotyp
show
mous
model
igg
monoclon
antibodi
mab
high
neutral
titer
protect
iga
antibodi
lower
neutral
titer
rsvspecif
cmi
lead
advantag
immunopatholog
endpoint
acut
infect
resolv
acut
infect
appear
requir
presenc
ctl
peak
activ
level
coincid
viru
clearanc
period
rsv
shed
prolong
anim
patient
lack
function
cell
cannon
et
al
bangham
et
al
ctl
present
circul
person
known
primari
exposur
cell
elimin
rsv
infect
anim
ctl
play
import
role
viral
clearanc
believ
contribut
substanti
prevent
reinfect
larg
respons
shortliv
two
curiou
aspect
immun
rsv
first
natur
infect
fail
result
resist
reinfect
fact
repeat
infect
occur
throughout
life
hall
et
al
second
pulmonari
diseas
follow
infect
appear
result
mainli
host
immun
inflammatori
respons
varga
bracial
situat
exagger
follow
use
formalininactiv
vaccin
children
mani
vaccin
recipi
develop
sever
diseas
sever
lethal
follow
natur
infect
rsv
kapikian
et
al
explan
ineffect
untoward
immun
respons
rsv
remain
obscur
thu
infect
induc
neutral
antibodi
product
well
tcell
respons
peptid
viral
protein
unknown
reason
infect
occur
presenc
neutral
antibodi
tcell
immun
latter
form
immun
howev
brief
durat
especi
respiratori
tract
varga
bracial
solut
immun
mysteri
like
emerg
ongo
studi
anim
model
system
mention
previous
sever
anim
model
avail
studi
rsv
immunopatholog
none
ideal
recent
progress
come
studi
balbc
mous
strain
anim
possibl
simul
vaccineinduc
pulmonari
diseas
exampl
rsv
g
proteinspecif
cell
transfer
mice
subsequ
rsvinfect
pulmonari
diseas
reminisc
vaccin
children
occur
alwan
et
al
approach
sinc
confirm
memori
cell
respons
g
protein
respons
pulmonari
immunopatholog
surprisingli
balbc
mice
singl
peptid
g
protein
recogn
epitop
memori
cell
involv
highli
oligoclon
varga
et
al
cell
recogn
peptid
either
effector
phenotyp
cell
although
minor
popul
respons
lesion
varga
et
al
cell
also
play
role
immunopatholog
sinc
serv
influenc
phenotyp
g
proteinspecif
cell
involv
thu
adopt
transfer
model
describ
previous
cotransf
proteinspecif
cell
along
gspecif
cell
result
diminish
patholog
alwan
et
al
moreov
incorpor
mhc
class
irestrict
epitop
g
protein
construct
use
prime
injuryprovok
memori
cell
reduc
pulmonari
diseas
express
srikiatkhachorn
bracial
thu
tcell
respons
protect
lesson
futur
vaccin
design
unfortun
environ
lung
perhap
exposur
one
rsv
protein
appear
impair
function
cell
addit
cell
persist
briefli
lung
resid
cell
lung
impair
antigeninduc
cytokin
product
compromis
protect
efficaci
chang
bracial
exact
mechan
cell
function
damag
understood
mechanist
resolut
could
lead
design
effect
vaccin
rsv
recent
year
evid
mount
infecti
rsv
individu
rsv
protein
capabl
modul
innat
antigenspecif
host
immun
respons
f
protein
implic
contactmedi
impair
peripher
blood
lymphocyt
pbl
prolifer
schlender
et
al
pbl
expos
rsvinfect
cell
cell
express
f
protein
absenc
infecti
rsv
arrest
g
g
phase
activ
marker
could
still
induc
surfac
cell
use
tcell
mitogen
rsv
nonstructur
protein
shown
separ
studi
coordin
antagon
antivir
effect
type
ifn
schlender
et
al
effect
observ
human
bovin
rsv
function
effect
cell
homolog
speci
use
f
protein
also
shown
augment
innat
immun
receptor
tolllik
receptor
induc
proinflammatori
cytokin
kurt
jone
et
al
recent
chemokin
receptor
shown
facilit
rsv
infect
g
glycoprotein
bind
short
region
g
shown
moder
amino
acid
homolog
fractalin
chemokin
identifi
thu
far
tripp
et
al
recent
studi
indic
glycoprotein
g
chemokin
activ
block
antig
antibodi
g
glycoprotein
respons
gener
enhanc
diseas
caus
inactiv
rsv
tripp
person
commun
final
studi
cell
infiltr
lung
parenchyma
balbc
mice
show
impair
cytolyt
activ
cytokin
secret
chang
brachial
impair
appear
attribut
tcellreceptor
signal
defect
turn
depend
upon
pulmonari
infect
rsv
thu
seem
clear
rsv
develop
number
mechan
alter
curtail
host
immun
respons
preced
section
document
difficulti
associ
develop
safe
effect
vaccin
rsv
oneto
infant
popul
like
develop
rsv
infect
requir
hospit
constitut
critic
target
group
rsv
vaccin
live
viru
vaccin
tend
immunogen
type
vaccin
age
matern
antibodi
immunolog
matur
render
immun
system
refractori
antigen
stimul
unfortun
live
viru
vaccin
also
pose
potenti
risk
sinc
insuffici
attenu
viru
may
actual
caus
diseas
young
infant
addit
candid
rsv
vaccin
must
induc
robust
circul
titer
neutral
antibodi
sinc
shown
play
instrument
role
protect
reinfect
final
candid
vaccin
rsv
need
care
evalu
ensur
caus
diseas
enhanc
primari
exposur
wildtyp
viru
associ
formalininactiv
vaccin
kapikian
et
al
although
vaccin
current
licens
rsv
varieti
vaccin
develop
strategi
assess
includ
involv
peptid
jiang
et
al
subunit
simo
et
al
goetsch
et
al
power
et
al
princ
et
al
viru
vector
dollenmai
et
al
schmidt
et
al
plasmid
dnarna
andersson
et
al
fleeton
et
al
live
attenu
vaccin
crow
et
al
wright
et
al
subunit
peptid
vaccin
provid
higher
level
safeti
vector
live
viru
vaccin
gener
disadvantag
fail
induc
protect
level
neutral
antibodi
primarili
due
fact
neutral
antibodi
rsv
direct
matur
membraneboundvirionassoci
form
f
subunit
peptid
vaccin
present
immatur
form
f
least
two
subunitpeptid
rsv
vaccin
activ
pursu
one
purifi
prepar
f
glycoprotein
glycoprotein
g
specif
peptid
conjug
albuminbind
site
streptococcu
g
protein
serv
carrier
function
neither
appear
suffici
immunogen
young
infant
target
use
older
children
elderli
effort
made
address
need
induc
adequ
level
neutral
antibodi
express
f
glycoprotein
suitabl
vector
one
studi
exampl
immunogen
human
rhinoviru
replicon
express
rsv
f
protein
evalu
mice
major
f
protein
produc
immatur
form
fraction
express
matur
form
titer
neutral
antibodi
readili
measur
immun
anim
dollenmai
et
al
similar
observ
made
rsv
glycoprotein
express
vaccinia
bovin
parainfluenza
viru
crow
schmidt
et
al
plasmid
dna
vaccin
transfect
cell
administr
lead
transient
express
immunogen
antigen
approach
demonstr
effect
mice
use
recombin
construct
contain
either
rsv
f
g
protein
sfv
express
system
fleeton
et
al
howev
scant
evid
approach
prove
suffici
immunogen
humansth
pursuit
live
attenu
rsv
vaccin
begun
yield
promis
result
one
potenti
advantag
live
attenu
rsv
vaccin
also
possibl
applic
plasmid
dna
vector
vaccin
possibl
intranas
administrationthi
immun
strategi
demonstr
mimic
natur
rsv
infect
induc
neutral
antibodi
respons
nasopharyng
mucosum
serum
well
cellmedi
immun
crow
initi
live
candid
rsv
vaccin
deriv
convent
fashion
passag
viru
repeatedli
cultur
low
temperatur
lead
strain
rsv
attenu
chimp
well
seroposit
adult
children
crow
viru
mutagen
chemic
produc
seri
temperaturesensit
mutant
clearli
attenu
remain
capabl
caus
transient
respiratori
ill
infant
administ
intranas
furthermor
mutat
shown
capabl
revert
replic
vivo
mcintosh
et
al
howev
extens
sequenc
data
provid
catalog
specif
temperaturesensit
mutat
rsv
next
gener
candid
rsv
vaccin
creat
use
sitedirect
mutat
use
best
current
gener
attenu
strain
start
point
cdna
copi
viru
produc
variou
character
mutat
introduc
whereupon
cdna
copi
transfect
cell
produc
infecti
virion
new
vaccin
strain
approach
multipl
attenu
mutat
point
mutat
gene
insert
delet
introduc
rsv
evalu
independ
combin
immunogen
pathogen
stabil
test
anim
human
possibl
introduc
immunomodulatori
gene
rsv
live
viru
vaccin
also
explor
mean
drive
antirsv
toward
cytokin
profil
concomitantli
reduc
risk
caus
vaccineenhanc
ill
parainfluenza
virus
piv
singlestrand
negativesens
rna
virus
belong
famili
paramyxovirida
envelop
virus
display
two
glycoprotein
hemagglutininneuraminidas
hn
fusion
f
protein
major
antibodi
respons
gener
four
distinct
serolog
type
identifi
term
human
piv
major
caus
acut
respiratori
infect
particularli
infant
young
children
respons
major
case
croup
second
frequent
etiolog
agent
rsv
pediatr
lower
respiratori
diseas
recent
piv
predominantli
shown
caus
acut
pneumonia
persist
infect
death
immunocompromis
patient
estim
unit
state
respons
case
pediatr
respiratori
diseas
requir
hospit
murphi
et
al
piv
subtyp
exhibit
clear
differ
epidemiolog
lesser
extent
occur
commonli
fall
winter
month
wherea
infect
occur
yearround
peak
infect
spring
summer
laurichess
et
al
effect
control
matern
antibodi
infant
delay
onset
diseas
caus
subtyp
preschool
year
infect
unimpair
matern
antibodi
half
children
seroconvert
subtyp
first
year
life
glezen
et
al
common
influenza
rsv
reinfect
homolog
subtyp
occur
even
presenc
virusspecif
antibodi
gener
reinfect
restrict
upper
respiratori
tract
probabl
serum
igg
present
lung
endur
longer
secretori
iga
upper
respiratori
tract
predomin
humor
immun
respons
direct
hn
f
involv
viru
attach
fusion
respect
serum
igg
siga
antibodi
produc
respons
piv
infect
contribut
viral
clearanc
uncertain
tcell
immun
thought
play
import
role
recoveri
piv
infect
sinc
dissemin
diseas
includ
spread
brain
occur
tcellimmunosuppress
patient
fishout
et
al
viru
shed
also
tend
prolong
person
impair
cellmedi
immun
respons
rabella
et
al
addit
support
particip
cellmedi
immun
piv
recoveri
come
studi
mice
particip
ctl
effect
viru
clearanc
absenc
cell
type
hou
et
al
convers
patient
bronchiol
display
elev
level
lymphocyt
transform
suggest
immunopathogen
respons
may
occur
matern
acquir
antipiv
antibodi
appear
protect
infant
sever
lower
respiratori
tract
diseas
infant
suggest
import
role
humor
immun
howev
nasal
wash
iga
produc
infant
primari
infect
usual
unabl
neutral
viru
adult
piv
ill
spread
rare
instanc
lower
respiratori
tract
nonetheless
piv
increasingli
identifi
caus
agent
seriou
respiratori
ill
elderli
care
facil
rate
pneumonia
popul
report
high
death
due
piv
also
confirm
piv
also
shown
exacerb
chronic
obstruct
pulmonari
diseas
elderli
given
complex
variabl
patholog
piv
compound
uncertainti
rel
contribut
variou
facet
immun
control
infect
vaccin
develop
virus
somewhat
problemat
vaccin
licens
date
nonetheless
sever
approach
piv
vaccin
develop
current
investig
earli
candid
vaccin
formalininactiv
fail
provid
protect
piv
infect
diseas
fortun
contrast
experi
inactiv
rsv
vaccin
enhanc
piv
diseas
infant
consequ
vaccin
formalininactiv
piv
vaccin
chin
et
al
two
vaccin
candid
live
chimer
vaccin
hn
f
human
recombin
bovin
schmidt
et
al
coldadapt
vaccin
strain
karron
et
al
undergon
clinic
trial
determin
safe
immunogen
seroneg
infant
month
age
number
attempt
made
develop
liveattenu
intranas
vaccin
temperaturesensit
coldadapt
piv
howev
attenu
piv
strain
discov
retain
capac
infect
central
neuron
nasal
caviti
potenti
caus
advers
event
central
nervou
system
mori
et
al
thu
strategi
oral
immun
vaccin
investig
mice
altern
approach
establish
antipiv
mucos
immun
strategi
found
provid
protect
yet
attempt
primat
human
subject
addit
purifi
hn
f
viral
vector
express
protein
immunogen
variou
anim
model
yet
evalu
primat
human
hamster
cotton
rat
mice
ferret
use
small
anim
model
evalu
candid
piv
vaccin
chimpanze
also
employ
recent
evid
suggest
african
green
monkey
provid
superior
anim
model
assess
live
piv
vaccin
durbin
et
al
seem
brink
develop
accept
piv
vaccin
recent
effort
appli
techniqu
revers
genet
could
lead
develop
vaccin
strain
lack
neurotrop
would
thu
suitabl
nasal
administr
payoff
power
new
techniqu
yet
materi
prospect
appear
promis
human
adenovirus
larg
famili
doublestrand
dna
virus
compris
serotyp
divid
six
subgroup
af
small
number
serotyp
subgroup
b
c
estim
caus
respiratori
diseas
children
respiratori
ill
adult
children
adenoviru
infect
caus
sever
interstiti
pneumonia
result
rare
death
symptomat
respiratori
infect
usual
febril
often
accompani
conjunct
condit
person
hous
close
quarter
militari
barrack
dormitori
longtermcar
facil
adenovirus
caus
largescal
epidem
acut
respiratori
diseas
subgroup
virus
also
associ
pneumonia
immunocompromis
patient
neutral
antibodi
direct
capsid
protein
hexon
fiber
protein
consid
primarili
respons
prevent
reinfect
adenoviru
virus
caus
upper
lower
respiratori
diseas
serum
antibodi
appear
role
protect
immun
horwitz
highli
effect
live
viru
vaccin
serotyp
administ
militari
recruit
vaccin
administ
oral
enter
coat
capsul
viru
attenu
nasopharyng
caviti
could
replic
gastrointestin
tract
without
caus
diseas
gener
protect
respons
upper
lower
respiratori
tract
howel
et
al
vaccin
went
product
suppli
unfortun
exhaustedth
loss
vaccin
alreadi
precipit
respiratori
diseas
epidem
among
militari
recruit
adenoviru
reemerg
lead
caus
febril
respiratori
diseas
popul
similarli
construct
quadrival
vaccin
serotyp
develop
assess
use
children
sinc
serotyp
caus
adenovirusassoci
respiratori
diseas
young
children
schmidt
et
al
sinc
recombin
adenovirus
effici
transfer
foreign
gene
host
cell
vivo
great
deal
attent
focus
use
virus
vector
express
recombin
gene
gene
therapi
carrol
et
al
achiev
delet
region
wildtyp
viral
genom
adenovirus
use
gene
therapi
extens
gene
delet
thu
replic
normal
cell
primari
interest
adenoviru
vector
use
correct
gene
defect
cystic
fibrosi
make
certain
cancer
immunogen
similarli
wellcharacter
immun
modulatori
effect
virus
explor
mean
control
autoimmun
diseas
transplant
reject
human
rhinovirus
hrv
nonenvelop
positivestrand
rna
virus
famili
picornavirida
antigen
distinct
serotyp
identifi
hrv
etiolog
agent
respons
common
cold
hrv
highli
infecti
replic
rapidli
epithelium
adjac
lymphoid
tissu
upper
respiratori
tract
caus
symptom
day
usual
lesion
confin
upper
respiratori
tract
mostli
nose
rare
pneumonia
occur
recoveri
occur
quickli
appear
depend
mainli
innat
defens
mechan
especi
ifn
characterist
nasal
serum
antibodi
appear
late
infect
delay
day
primari
diseas
titer
may
continu
rise
week
infect
immun
develop
stabl
longlast
year
howev
remain
uncertain
whether
serum
igg
transud
nasal
iga
defend
reinfect
couch
mani
antigen
distinct
serotyp
occur
natur
infect
homotyp
vaccin
develop
prevent
hrv
infect
theoret
possibl
probabl
practic
first
isol
human
coronavirus
envelop
positivestrand
rna
virus
larg
genom
virus
classifi
two
serotyp
design
simpli
repres
respect
strain
coronavirus
estim
caus
common
cold
diseas
longer
incub
shorter
cours
diseas
due
rhinovirus
occasion
coronavirus
caus
sever
lower
respiratori
tract
diseas
infant
small
children
recoveri
infect
leav
patient
immun
durat
immun
shorter
rhinovirus
holm
mechan
immun
understood
attempt
made
develop
vaccin
human
coronaviru
infect
situat
may
chang
april
world
suddenli
becom
awar
coronavirus
human
pathogen
around
novemb
new
coronaviru
strain
appear
southern
china
repres
major
respiratori
pathogen
syndrom
term
sar
sever
acut
respiratori
syndrom
ksiazek
et
al
drosten
et
al
unlik
previous
describ
coronaviru
strain
usual
caus
mild
upper
respiratori
tract
lesion
sar
strain
affect
lower
tract
markedli
damag
alveolar
epitheli
cell
may
becom
virem
furthermor
infect
result
death
commun
mortal
rate
may
high
modern
travel
rapidli
dissemin
viru
around
world
given
high
mortal
lack
effect
antivir
therapi
vaccin
caus
consider
alarm
origin
new
viru
remain
unknown
genom
structur
suggest
zoonosi
recombin
anim
human
strain
nation
institut
health
nih
govern
countri
process
significantli
fund
coronaviru
research
find
improv
mean
diagnosi
treatment
control
mention
vaccin
avail
human
coronaviru
anim
coronavirus
control
vaccin
efficaci
well
establish
ladman
et
al
appear
like
vaccin
sar
strain
repres
high
prioriti
issu
futur
exampl
formalininactiv
rsv
vaccin
illustr
potenti
hazard
immun
human
aim
induc
protect
immun
mucos
surfac
mucos
surfac
continu
visit
larg
varieti
foreign
albeit
mostli
harmless
antigen
local
immun
system
predispos
hyporespons
materi
perturb
caus
invad
microb
bacteria
virus
thought
arm
mucos
surfac
state
respons
consequ
nasal
administ
vaccin
virus
care
design
exhibit
limit
virul
may
insuffici
disturb
mucos
surfac
gener
effect
immun
respons
addit
even
prepar
suffici
immunogen
resid
antigenpres
cell
concert
lymphocyt
direct
individu
respons
toward
domin
neurath
et
al
cytokin
profil
secret
activ
cell
promot
develop
antigenspecif
cytotox
lymphocyt
cell
promot
activ
b
cell
produc
specif
antibodi
includ
siga
antibodi
respons
make
import
contribut
resolut
respiratori
infect
overproduct
polar
immun
respons
toward
cell
hyperact
lead
allerg
respons
asthma
neurath
et
al
similarli
activ
transcript
factor
tbet
lead
hyperrespons
lead
immunopatholog
respons
seen
crohn
diseas
ouyang
et
al
thu
respiratori
viral
vaccin
includ
materi
coadminist
enhanc
immunogen
must
care
evalu
ensur
lack
capac
induc
harm
immun
respons
recipi
varieti
experiment
adjuv
evalu
abil
improv
immunogen
mucos
vaccin
two
wide
investig
adjuv
heatlabil
enterotoxin
escherichia
coli
lt
cholera
toxin
ct
pizza
et
al
normal
lt
shown
much
toxic
use
adjuv
howev
studi
nasal
immun
mice
demonstr
mutat
lt
lack
toxic
adpribosyl
activ
provid
adjuv
effect
compar
intact
heterodim
likewis
ct
shown
caus
inflamm
enhanc
product
ige
antibodi
like
preclud
use
adjuv
human
select
mutat
ct
result
reduc
toxic
variant
retain
adjuv
anoth
adjuv
show
promis
nasal
immun
cpg
oligodeoxynucleotid
odn
unmethyl
cpg
oligonucleotid
motif
occur
commonli
bacteri
dna
trigger
immun
respons
mammal
studi
nasal
immun
use
cpg
odn
adjuv
show
materi
enhanc
humor
cellmedi
respons
well
toler
mckluski
davi
moldoveanu
et
al
anoth
pair
experiment
adjuv
investig
nasal
administr
proteosom
emulsom
shown
anim
studi
polar
immun
toward
cytokin
profil
proteosom
complex
neisseri
membran
protein
lipopolysaccharid
shigella
flexneri
plesiomona
shigelloid
induc
cytokin
mice
respons
nasal
coadminist
influenza
ha
jone
et
al
emulsom
lipoid
particul
vehicl
compris
hydrophob
solid
fat
core
surround
stabil
one
phospholipid
bilay
emulsom
shown
mice
enhanc
nasal
immunogen
polar
respons
toward
cytokin
profil
lowel
et
al
coadministr
nasal
influenza
vaccin
cytokin
also
evalu
mice
found
substanti
enhanc
protect
antibodi
respons
obtain
vaccin
alon
arulanandam
et
al
one
signific
drawback
vaccin
strategi
virus
influenza
induc
homotyp
usual
transient
immun
continu
revaccin
requir
tcell
immun
primarili
direct
nonvari
intern
antigen
virus
heterotyp
immun
potenti
provid
crossprotect
recurr
diseas
unfortun
cmi
respons
respiratori
virus
appear
declin
rather
rapidli
woodland
recent
studi
mice
reveal
longterm
cmi
respons
gener
particularli
use
dna
vaccin
studi
still
rel
earli
may
eventu
lead
vaccin
strategi
target
induct
longterm
crossreact
tcell
immun
could
reduc
requir
revaccin
complex
mucos
immun
system
thu
present
daunt
challeng
vaccinologist
mani
strategi
studi
enorm
promis
must
examin
great
care
guard
equal
great
capac
inadvert
harm
respiratori
viru
infect
major
caus
human
diseas
none
satisfactorili
control
vaccin
infect
licens
vaccin
exist
reason
situat
like
multipl
includ
fact
antigen
mobil
exist
multipl
serotyp
moreov
none
persist
beyond
usual
brief
infectiondiseas
episod
henc
continu
sourc
antigen
investig
maintain
necessari
sustain
function
longterm
memori
ahm
gray
addit
evid
sinc
pioneer
work
tomasi
ogra
biolog
immun
mucos
surfac
differ
central
system
immun
tomasi
et
al
ogra
karzon
initi
focu
type
antibodi
involv
thu
siga
usual
princip
ig
isotyp
mucos
site
mainli
produc
lymphoid
tissu
associ
mucos
surfac
tomasi
et
al
seem
halflif
iga
less
igg
domin
system
immun
longterm
presenc
ig
requir
cell
continu
produc
argu
iggproduc
plasma
cell
exist
long
period
least
bone
marrow
slifka
ahm
clear
similar
longterm
igaproduc
plasma
cell
also
exist
mucosaassoci
lymphoreticular
tissu
malt
absent
could
account
loss
protect
iga
mucos
surfac
contemporari
research
focus
tcell
immun
especi
immunolog
memori
basi
protect
vaccin
discuss
previous
cell
especi
cell
particip
immun
respiratori
viru
infect
howev
unlik
neutral
antibodi
function
imped
infect
instead
cell
serv
effect
recoveri
infect
process
involv
cytotox
cytokin
product
follow
infect
effectormemori
cell
induc
lung
tissu
respons
mainli
control
infect
cell
exert
direct
protect
effect
maintain
function
nonlymphoid
parenchym
tissu
lung
time
howev
month
effector
memori
cell
activ
bare
detect
stage
selfrenew
memori
cell
present
central
lymphoid
tissu
may
persist
year
seemingli
without
need
antigen
restimul
sustain
sprent
tough
wherri
et
al
issu
howev
remain
debat
hogan
et
al
addit
clear
mucos
lymphoid
nonlymphoid
site
similarli
act
repositori
memori
cell
howev
suggest
mucos
memori
shorter
durat
central
memori
hogan
et
al
wherev
noneffector
memori
cell
exist
take
day
recruit
effector
memori
cell
lung
tissu
meanwhil
rapidli
replic
respiratori
viru
could
well
establish
process
caus
lesion
anoth
unresolv
issu
locat
cell
recruit
activ
follow
reinfect
becom
lung
effector
memori
cell
conceiv
mucos
lymphoid
site
cell
inde
disappear
quickli
antigen
exposur
experi
shown
central
lymphoid
organ
provid
sourc
protect
cell
long
initi
infect
wherri
et
al
could
form
antigen
reexposur
might
preferenti
recruit
sourc
cell
addit
conceiv
certain
form
vaccin
may
induc
readili
recruit
form
memori
cell
lymphoid
tissu
novel
adjust
might
serv
influenc
event
anticip
ongo
fundament
research
mucos
central
memori
reveal
clue
exploit
improv
efficaci
respiratori
viral
vaccin
hope
futur
rewrit
review
abl
report
posit
progress
issu
